General Information

General Information

DRAVP ID DRAVPe01723

Peptide Name P4(SARS-CoV (1153–1182))

Sequence GINASVVNIQKEIDRLNEVAKNLNESLIDL

Sequence Length 30

UniProt ID P59594

Taxon ID None

Source Synthetic construct

Validation Experimentally Validated

Origin Information

Gene Name/ID Not Available

GenBank Not Available

Amino Acid position Not Available

Domain Accession ID Not Available

Nucleotide sequence ID Not Available

Molecular Type Not Available

Chromosomal Position Not available

Activity Information

Target Organism SARS-CoV

Assay cell fusion inhibition assay

Activity

[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.80 ± 0.21 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.17 ± 0.24 μM).

Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity

[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.

Binding Target membrane

Mechanism Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.

Structure Information

PDB ID None

Predicted Structure Download No predicted structure available

Linear/Cyclic Linear

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Stereochemistry L

Physicochemical Information

Formula C143H245N41O49

Absent amino acids CFHMPTWY

Common amino acids N

Mass 3322.76

Pl 4.51

Basic residues 3

Acidic residues 5

Hydrophobic residues 13

Net charge -2

Boman Index -5339

Hydrophobicity -11.33

Aliphatic Index 139.67

Half Life

Mammalian:30 hour
Yeast:>20 hour
E.coli:>10 hour

Extinction Coefficient cystines 0

Absorbance 280nm 0

Polar residues 8

Literature Information

Literature 1

Title Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.

Pubmed ID 18983873

Reference Antiviral Res. 2009 Jan;81(1):82-7.

Author Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.

DOI 10.1016/j.antiviral.2008.10.001